Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 7/20 | 0.56 |
| ▸ | ITPR2 | Q14571 | 3/20 | 0.54 |
| ▸ | ITPR1 | Q14643 | 3/20 | 0.54 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.54 |
| ▸ | AKT1 | P31749 | 1/20 | 0.54 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.52 |
| ▸ | INPP5A | Q14642 | 3/20 | 0.48 |
| ▸ | FDPS | P14324 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710149 | 1.00 | ITPR3 (0.56) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL3498450 | 1.00 | ITPR3 (0.56) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL29602097 | 1.00 | ITPR3 (0.56) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL30629453 | 1.00 | ITPR3 (0.56) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL6708568 | 1.00 | ITPR3 (0.56) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL3500008 | 1.00 | ITPR3 (0.56) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL613185 | 1.00 | ITPR3 (0.56) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL30713458 | 1.00 | ITPR3 (0.56) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| Scyllitol SCHEMBL5997336 | 0.91 | ITPR3 (0.64) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL4343592 | 0.91 | ITPR3 (0.74) | ITPR3ITPR2ITPR1INPPL1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260071221-A1 | Fibroblast Growth Factor (FGF)21 Inhibition for Treatment of Cardiac Hypertrophy | UNIVERSITY OF CINCINNATI (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250197875-A1 | ENGINEERED PLANTS HAVING MODIFIED INOSITOL PYROPHOSPHATES | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2025-06-19 | — | — | US | disclosed |
| US-20250154477-A1 | NUDIX OVEREXPRESSING ENGINEERED PLANTS AND USES THEREOF | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2025-05-15 | — | — | US | disclosed |
| US-20240409928-A1 | NOVEL RNA TRANSCRIPT | PTC THERAPEUTICS, INC. | 2024-12-12 | — | — | US | disclosed |
| WO-2023178098-A2 | ENGINEERED PLANTS HAVING MODIFIED INOSITOL PYROPHOSPHATES | VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023141501-A2 | NUDIX OVEREXPRESSING ENGINEERED PLANTS AND USES THEREOF | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20230220018-A1 | HETEROLOGOUS DDP1 EXPRESSING PLANTS AND USES THEREOF | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2023-07-13 | — | — | US | disclosed |
| CN-115161396-B | Application of PPIP5K2 and compound thereof in regulating and controlling ovarian cancer progression | 四川大学华西第二医院 | 2023-04-07 | — | — | CN | disclosed |
| CN-115232874-B | Application of long-chain non-coding RNA in regulation and control of ovarian cancer progression | 四川大学华西第二医院 | 2023-04-07 | — | — | CN | disclosed |
| CN-115232874-A | Application of long-chain non-coding RNA in regulation and control of ovarian cancer progression | 四川大学华西第二医院 | 2022-10-25 | — | — | CN | disclosed |
| CN-115161396-A | Application of PPIP5K2 and compound thereof in regulating and controlling ovarian cancer progression | 四川大学华西第二医院 | 2022-10-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071221-A1 | Fibroblast Growth Factor (FGF)21 Inhibition for Treatment of Cardiac Hypertrophy | FGF23, FGF1, FGF2 | ITPR3 4501/4885ITPR2 4415/4885ITPR1 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.